Form 8-K - Current report:
SEC Accession No. 0001140361-22-038231
Filing Date
2022-10-24
Accepted
2022-10-24 16:31:02
Documents
12
Period of Report
2022-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K brhc10043208_8k.htm   iXBRL 8-K 26410
  Complete submission text file 0001140361-22-038231.txt   162877

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btx-20221018.xsd EX-101.SCH 3872
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20221018_lab.xml EX-101.LAB 22547
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20221018_pre.xml EX-101.PRE 16050
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10043208_8k_htm.xml XML 4237
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221326316
SIC: 2834 Pharmaceutical Preparations